Axillary Hyperhidrosis - Pipeline Review, H1 2018

  • ID: 4482762
  • Report
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Brickell Biotech Inc
  • Dermira Inc
  • GlaxoSmithKline Plc
  • TheraVida Inc
  • MORE
Axillary Hyperhidrosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H1 2018, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II and Phase I stages are 1, 4 and 1 respectively.

Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Allergan Plc
  • Brickell Biotech Inc
  • Dermira Inc
  • GlaxoSmithKline Plc
  • TheraVida Inc
  • MORE
Introduction

Report Coverage

Axillary Hyperhidrosis - Overview

Axillary Hyperhidrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Axillary Hyperhidrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Axillary Hyperhidrosis - Companies Involved in Therapeutics Development

Allergan Plc

Brickell Biotech Inc

Dermira Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

GlaxoSmithKline Plc

TheraVida Inc

Axillary Hyperhidrosis - Drug Profiles

(oxybutynin + pilocarpine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

botulinum toxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrrolate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glycopyrronium tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sofpironium bromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

umeclidinium bromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Axillary Hyperhidrosis - Dormant Projects

Axillary Hyperhidrosis - Discontinued Products

Axillary Hyperhidrosis - Product Development Milestones

Featured News & Press Releases

Feb 20, 2018: Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

Feb 17, 2018: New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology

Feb 12, 2018: Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference

Nov 06, 2017: Dermira Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis

Oct 24, 2017: Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis

Oct 13, 2017: Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference

Sep 13, 2017: Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients

Sep 07, 2017: Dermira To Present New Data on Phase 3 Glycopyrronium Tosylate Clinical Program At Leading European Dermatology Congress

Mar 21, 2017: Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting

Mar 17, 2017: Dermira to Present Data on Glycopyrronium Tosylate Clinical Program at Annual Maui Derm Meeting

Mar 03, 2017: Dermira Presents New Data in Primary Axillary Hyperhidrosis at American Academy of Dermatology 2017 Annual Meeting

Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis

Feb 27, 2017: Dermira Data from DRM04 Clinical Program to Be Presented at American Academy of Dermatology Annual Meeting

Oct 13, 2016: Dermira to Present Data from DRM04 Clinical Program at Fall Clinical Dermatology Conference

Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Axillary Hyperhidrosis, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Axillary Hyperhidrosis - Pipeline by Allergan Plc, H1 2018

Axillary Hyperhidrosis - Pipeline by Brickell Biotech Inc, H1 2018

Axillary Hyperhidrosis - Pipeline by Dermira Inc, H1 2018

Axillary Hyperhidrosis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2018

Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline Plc, H1 2018

Axillary Hyperhidrosis - Pipeline by TheraVida Inc, H1 2018

Axillary Hyperhidrosis - Dormant Projects, H1 2018

Axillary Hyperhidrosis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Axillary Hyperhidrosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Allergan Plc
  • Brickell Biotech Inc
  • Dermira Inc
  • Dr. August Wolff GmbH & Co KG Arzneimittel
  • GlaxoSmithKline Plc
  • TheraVida Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll